Comparative characteristics of hypolipidemic drugs for the rational management of the pharmacy range

Authors

DOI:

https://doi.org/10.24959/sphhcj.25.366

Keywords:

price analysis; drug availability; hypolipidemic drugs; marketing research; pharmacoeconomic studies; pharmaceutical market

Abstract

The high prevalence of cardiovascular diseases in Ukraine and the world ensures a consistently high demand for hypolipidemic drugs. The rational formation of the pharmacy range of these drugs is a key task for the pharmaceutical industry and affects the effectiveness of therapy, patient adherence and economic availability of treatment.

Aim. To analyze the most in-demand and physically available hypolipidemic drugs in the pharmaceutical market of Ukraine, taking into account their economic and physical accessibility for the rational formation of used pharmacy range.

Materials and methods. The study used the content analysis methods to systematically collect and process data on lipid-lowering drugs. The drugs were grouped according to active ingredients, manufacturers, and average retail prices to identify key trends in the range formation. Economic accessibility was assessed based on the cost of the defined daily dose (DDD) for the main indication in adults, which allowed to compare treatment costs between drugs from different manufacturers. Data were collected in June 2025 and from scientific publications covering the period of 2018–2025.

Results and discussion. A total of 319 lipid-lowering drugs registered in Ukraine as of June 1, 2025, were analyzed. Statins accounted for the largest share (84 %), confirming their dominance in the treatment of dyslipidemia. Foreign-manufactured drugs comprised 83 % of the range, while domestic medicines accounted for only 17 %. Monotherapy drugs predominated in the market (86 %), whereas combined drugs made up only 14 %. The example of the drug “Tricor®” demonstrated significant differences in the physical availability of hypolipidemic drugs in different cities of Ukraine. The analysis of economic accessibility using the DDD cost method revealed variability in the cost – from 1.15 UAH to 7.85 UAH per DDD – and the monthly cost of lipid-lowering therapy ranged from 34.50 UAH to 235.50 UAH.

Conclusions. The analysis conducted will allow pharmacy managers and pharmacists to make informed decisions regarding the management of the hypolipidemic drug range, taking into account both physical availability and economic accessibility.

References

  1. Shchorichnyi zvit pro stan zdorovia naselennia Ukrainy ta epidemichnu sytuatsiiu za 2022 rik. (2023). Ministerstvo okhorony zdorovia Ukrainy. Kyiv. https://surl.li/himebu
  2. Smertnist v Ukraini. (n. d.). Opendatabot. https://opendatabot.ua/open/death-statistics?utm_source=chatgpt.com
  3. Jianu, N., Nițu, E.-T., Merlan, C., Foica, D., Sbârcea, L., Buda, V., Suciu, M., Lombrea, A., & Movilă, D. E. (2025). A comprehensive review of the latest approaches to managing hypercholesterolemia: A comparative analysis of conventional and novel treatments: Part I. Life, 15(8), 1185. https://doi.org/10.3390/life15081185
  4. Mormone, A., Tortorella, G., Esposito, F., Caturano, A., Marrone, A., Cozzolino, D., Galiero, R., Marfella, R., Sasso F. C., & Rinaldi, L. (2024). Advances in pharmacological approaches for managing hypercholesterolemia: A comprehensive overview of novel treatments. Biomedicines, 12(2), 432. https://doi.org/10.3390/biomedicines12020432
  5. Prabhakar, A. P., Vedamurthy, D., & Kalra, D. K. (2025). Impact of lipid lowering therapies on the primary prevention of atherosclerotic cardiovascular disease. Current Cardiovascular Risk Reports, 19(12). https://doi.org/10.1007/s12170-025-00764-x
  6. Zhadko, S. V., Babicheva, H. S., Pestun, I. V., & Sevriukov, O. V. (2025). Marketynhovi ta farmakoekonomichni doslidzhennia likarskykh zasobiv hrupy statyniv. News of Pharmacy, 1(109), 129–140. https://doi.org/10.24959/nphj.23.109.129
  7. Nemchenko, A. S., Popova, I. A., & Demchenko, N. V. (2024). Doslidzhennia farmatsevtychnoho zabezpechennia khvorykh na sertsevo-sudynni zakhvoriuvannia v ramkakh prohramy “Dostupni liky”. Health & Education, (1), 121–130. https://doi.org/10.32782/health-2024.1.16
  8. Tkachova, O., Iakovlieva, L., Mitkova, Z., Manova, M., Savova, A., & Petrova, G. (2019). An affordability of statins therapy – comparative analysis between Ukraine and Bulgaria. BMC Health Services Research, 19(1), 902–910. https://doi.org/10.1186/s12913-019-4736-3
  9. Guadamuz, J. S., Shooshtari, A., & Qato, D. M. (2022). Global, regional and national trends in statin utilisation in high-income and low/middle-income countries, 2015–2020. BMJ Open, 12(9), e061350. https://doi.org/10.1136/bmjopen-2022-061350
  10. Kotvitska, A. A., Cherkashyna, A. V., Volkova, A. V., & Kubarieva, I. V. (2018). Analysis of the current state and the dynamics of lipid-lowering drugs in the pharmaceutical market of Ukraine. Asian Journal of Pharmaceutical and Clinical Research, 11(6), 358–362. https://doi.org/10.22159/ajpcr.2018.v11i6.22702
  11. Ferrara, F., Zovi, A., Langella, R., Panico, A., Scognamiglio, M., & Trama, U. (2025). Consumption and expenditure of drugs used for the treatment of hypercholesterolemia: A governance analysis. Expert Review of Pharmacoeconomics & Outcomes Research, 25(6), 927–932. https://doi.org/10.1080/14737167.2025.2493728
  12. Mortensen, M., & Falk, E. (2018). Primary prevention with statins in the elderly. Journal of the American College of Cardiology, 71(1), 85–94. https://doi.org/10.1016/j.jacc.2017.10.080
  13. Jianu, N., Nițu, E.-T., Merlan, C., Nour, A., Buda, S., Suciu, M., Luca, S. A., Sbârcea, L., Andor, M., & Buda, V. (2025). A comprehensive review of the latest approaches to managing hypercholesterolemia: A comparative analysis of conventional and novel treatments: Part II. Pharmaceuticals, 18(8), 1150. https://doi.org/10.3390/ph18081150
  14. Derzhavnyi reiestr likarskykh zasobiv Ukrainy. (n. d.). http://www.drlz.com.ua/ibp/ddsite.nsf/all/shlist?opendocument
  15. Tryhubchak, O. V. (2018). Doslidzhennia asortymentu preparativ atsetylsalitsylovoi kysloty v kombinatsii zi statynom. Sotsialna farmatsiia v okhoroni zdorovia, 4(3), 80–86. http://nbuv.gov.ua/UJRN/sphhc_2018_4_3_12
  16. Hipolipidemichni zasoby (C10). (n. d.). Apteka Nyzkykh Tsin. https://anc.ua/atc/c10
  17. Nemchenko, A. S., Nazarkina, V. M., Mishchenko, V. I., & Vynnyk, O. V. (2018). Analiz ukrainskoho rynku parafarmatsevtykiv dlia profilaktyky keloidnykh rubtsiv. ScienceRise: Pharmaceutical Science, 2(12), 25–31. https://doi.org10.15587/2519-4852.2018.128867
  18. Indeks infliatsii v Ukraini. (n. d.). Minfin. https://index.minfin.com.ua/
  19. Guidelines for ATC classification and DDD assignment 2024 (27th ed.). (2023). WHO Collaborating Centre for Drug Statistics Methodology. Oslo: Norwegian Institute of Public Health. https://atcddd.fhi.no/ddd/definition_and_general_considera/

Downloads

Published

2025-09-04

How to Cite

Tkachova, O. V., Mishchenko, V. I. ., Zhadko, S. V. ., & Gerasymova, O. O. (2025). Comparative characteristics of hypolipidemic drugs for the rational management of the pharmacy range. Social Pharmacy in Health Care, 11(3), 78–86. https://doi.org/10.24959/sphhcj.25.366

Issue

Vol. 11 No. 3 (2025)

Section

Social marketing and pharmacoeconomic research

License

Copyright (c) 2025 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.